Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06371924

Immunometabolism of Machine Perfusion Strategies

Led by King's College Hospital NHS Trust · Updated on 2025-08-13

36

Participants Needed

2

Research Sites

66 weeks

Total Duration

On this page

Sponsors

K

King's College Hospital NHS Trust

Lead Sponsor

K

King's College London

Collaborating Sponsor

AI-Summary

What this Trial Is About

There are not enough donated livers for everybody who needs one, and as a result, thousands of patients worldwide are waiting for liver transplants, with many dying while waiting for a life-saving organ. One reason for this shortage is that some usable livers from donors who are considered of high risk are being thrown away out of concern that they might not work well after transplantation due to a problem called ischaemia reperfusion injury (IRI). The discarded organs are mostly those coming from donors who have died due to cardiac arrest (called 'donation after circulatory death' or DCD), with only 27% of them being used in the UK. The quality of these DCD organs could be improved by changing how they are preserved after being removed from the donor. The most commonly used strategy is still to remove the livers and put them in an icebox ('static cold storage' or SCS). The alternative approaches, which are more complex and expensive, but that can also improve the quality of the DCD livers, involve using machines to pump fluids through the livers ('machine perfusion' or MP). There are three MP methods being used in patients: 1) normothermic regional perfusion (NRP), which involves pumping the donor's blood through the liver after the donor has died but the liver is still in the donor's body; 2) normothermic machine perfusion (NMP), in which the liver is pumped with blood outside of the donor's body; and 3) hypothermic machine perfusion (HOPE), which is also used outside of the donor's body by pumping cold fluid into the liver. HOPE and NRP have been shown to improve how well DCD livers function after transplantation. NMP can also improve the quality of the DCD livers, but its main advantage is that it allows confirming that the donated liver functions well before proceeding with the transplant. Until now, there has not been a proper comparison of these methods, and the doctors do not understand well the mechanisms through which MP improves the quality of the DCD livers. The iInvestigators plan to conduct a study where 36 DCD human livers will be split into three groups: SCS, NRP, and HOPE. After that, they will be put in NMP to confirm that they are good enough to be transplanted and to study the mechanisms through which NRP, SCS and HOPE work.

CONDITIONS

Official Title

Immunometabolism of Machine Perfusion Strategies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Donor must be category III DCD considered for abdominal organ retrieval only
  • Donor age 18 years or older
  • Retrieval procedure allocated to KCH or UHB NORS teams
  • Donor liver accepted for a patient at KCH or UHB transplant waiting list via standard offering
  • Functional donor warm ischaemia period 30 minutes or less
  • Donor BMI less than 35 kg/m2
  • Predicted cold ischaemic time less than 8 hours
  • Donor family has consented to use liver for research
  • Recipients 18 years or older
  • Listed on an elective transplant waiting list
  • First liver transplantation
  • Suitable to receive a DCD graft based on liver listing MDT
  • Willingness to consent for study participation
Not Eligible

You will not qualify if you...

  • Donor is HIV, hepatitis B (HBV HbsAg) or hepatitis C (HCV RNA) positive; HBV anti-Hbc positive donors are allowed
  • Macroscopic evidence of liver fibrosis
  • Liver weight greater than 2.5 kg
  • Retrieval of cardiothoracic organs intended for transplantation
  • Any medical condition interfering with safe trial completion as judged by principal investigator
  • High-risk surgical candidates (e.g., extensive portomesenteric thrombosis, previous complex upper abdominal surgery)
  • Patients receiving super-urgent transplantation for acute or acute-on-chronic liver failure
  • Patients unable to give full informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University Hospitals Birmingham NHS Foundation Trust

Birmingham, United Kingdom, B15 2GW

Actively Recruiting

2

Royal Free London NHS Foundation Trust

London, United Kingdom, NW3 2QG

Actively Recruiting

Loading map...

Research Team

A

Alberto Sanchez-Fueyo

CONTACT

J

Jurate Wall

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here